✦ LIBER ✦

Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I

✍ Scribed by Markus Grompe; Muhsen Al-Dhalimy

Book ID: 102859775
Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 777 KB
Volume: 2
Category: Article
ISSN: 1059-7794
DOI: 10.1002/humu.1380020205

No coin nor oath required. For personal study only.

✦ Synopsis

Tyrosinemia type I is an autosomal recessive inborn error of metabolism caused by deficiency of the enzyme fumaryl acetoacetate hydrolase (FAH, EC 3.7.1.2.). We have used reverse transcription and the polymerize chain reaction to amplify the peptide coding region of the FAH cDNA from four patients with tyrosinemia type I. Chemical mismatch cleavage analysis and DNA sequencing were utilized to determine mutant alleles in all cases. A French Canadian patient was homozygous for a splice error mutation in the 3' portion of the gene. A second patient, from a consanguineous pedigree in Iran, had the identical splice alteration. The third patient has a missense mutation, changing valine to glycine in codon 166. And finally two nonsense mutations in codons 357 and 364 were found in the fourth patient. 0

📜 SIMILAR VOLUMES

Six novel mutations in the fumarylacetoa

Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I

✍ Cynthia Timmers; Markus Grompe 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB 👁 2 views

Mutations in the fumarylacetoacetate hyd

Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: Overview

✍ Maryse St-Louis; Robert M. Tanguay 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 2 views

Tyrosinemia type I is an inborn error of metabolism caused by a deficiency in the last enzyme of the tyrosine catabolic pathway, fumarylacetoacetate hydrolase (FAH). The disease has been reported worldwide with varying incidence. Recently, there has been considerable progress in identifying mutation

Structural organization and analysis of

Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I

✍ Awata, Hisataka; Endo, Fumio; Tanoue, Akito; Kitano, Akito; Nakano, Yoshikuni; M 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 406 KB

Spectrum of mutations in the fumarylacet

Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries

✍ AJIW Bergman; IET van den Berg; W Brink; BT Poll-The; JK Ploos van Amstel; R Ber 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 2 views

Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of

Correction of Fumarylacetoacetate Hydrol

Correction of Fumarylacetoacetate Hydrolase Deficiency (Type I Tyrosinemia) in Cultured Human Fibroblasts by Retroviral-Mediated Gene Transfer

✍ D. Phaneuf; M. Hadchouel; R.M. Tanguay; C. Brechot; N. Ferry 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 405 KB

Mutation analysis of the FAH gene in Isr

Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I

✍ Orly N. Elpeleg; Avraham Shaag; Elizabeth Holme; Ghaleb Zughayar; Suzi Ronen; Dr 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

Thirteen Israeli patients with type I tyrosinemia were studied. To the best of our knowledge, this group represents all of the patients that were diagnosed in Israel during the years 1987-1997. Their age of onset was variable but all the patients suffered from liver disease at presentation. Six died